FDA Rips Aegerion Exec For Drug Promo Claims On CNBC

Law360, New York (November 12, 2013, 6:40 PM EST) -- The U.S. Food and Drug Administration on Friday torched the CEO of Aegerion Pharmaceuticals Inc. for comments made on CNBC, saying viewers were left with the faulty impression that cholesterol drug Juxtapid isn’t risky and by itself can ensure they live long enough to "meet their grandkids."

According to an FDA warning letter, CEO Marc Beer twice was a guest this year on the financial news network’s show “Fast Money,” and made a number of unsubstantiated and misleading remarks about the orphan drug’s safety and effectiveness....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.